Avalo Therapeutics, Inc.
AVTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001534120
In the last 90 days, Avalo Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 126 institutions reported holding it in 13F filings for Q2 2026, worth $1.31B in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding Avalo Therapeutics, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Q4 2022 | Change |
|---|---|---|---|
| Holders | 27 | 28 | +1 |
| Shares | 5.55M | 5.55M | +927 (0.0%) |
| Value | $18.4M | $28.0M | +$9.56M (+51.9%) |
New holders (3)
Institutions that held Avalo Therapeutics, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Susquehanna International Group, LLP | 18,671 | $95.0K | 0.00% |
| Royal Bank of Canada | 416 | $2.00K | 0.00% |
| Clearstead Advisors, LLC | 27 | $136 | 0.00% |
Sold out (2)
Institutions that held Avalo Therapeutics, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| BNP Paribas Arbitrage, SA | 717 | $2.38K |
| New York State Common Retirement Fund | 1 | $0 |